Synced daily from ClinicalTrials.gov via AACT. Last sync: .
22 Nemolizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 11 indications (including Atopic Dermatitis & Moderate-to-Severe Atopic Dermatitis) and 6,388 total planned enrollment. 8 Phase 3 Nemolizumab trials and 9 Phase 2, 2 Phase 4 are listed. 5 Nemolizumab clinical trials are actively recruiting at 20 U.S. sites across 13 states. Most recent activity: NCT07352566 (Jun 2030).
Where to Participate: All Nemolizumab Trial Sites in the U.S. (20 sites across 13 states)
Every actively recruiting Nemolizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
NCT05056779withdrawnEfficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
All Nemolizumab trials (22)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
22 Nemolizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 14 are marked completed.
Are Nemolizumab clinical trials recruiting in 2026?
Yes — 4 Nemolizumab trials are actively recruiting in 2026, with 20 U.S. sites across 13 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Nemolizumab being studied for?
Nemolizumab is being studied for Atopic Dermatitis, Moderate-to-Severe Atopic Dermatitis, Prurigo Nodularis, Systemic Sclerosis, Psoriasis and 6 more. The trials are grouped by indication on this page.
What phase is Nemolizumab in?
Nemolizumab clinical trials span 2 Phase 4, 8 Phase 3, 9 Phase 2, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Nemolizumab clinical trials?
The lead sponsor across the most Nemolizumab trials is Galderma R&D, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nemolizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.